Jeffrey C Laurence, MD

Highlights

1
Translational research : the journal of laboratory and clinical medicine · 2020
CMCynthia Magro DADavid A Berlin SSSteven Salvatore JCJeffrey C Laurence
PMID: 32299776PMCID: PMC7158248DOISenior author1,817 citations
2
Clinical and experimental immunology · 2020
KVKoen Van Besien JCJeffrey C Laurence
PMID: 32681658PMCID: PMC7405159DOISenior author55 citations
3
PharmacoEconomics · 2020
JCJeffrey C Laurence
PMID: 31828738PMCID: PMC7045788DOISenior author17 citations

325

2 grants

Sub-PI
Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV
National Heart, Lung, and Blood Institute · 2023–2027 · via Oklahoma Medical Research Foundation
R01HL167656-04
PI
Role of MASP-2 in microvascular endothelial cell injury associated with severe COVID-19 and all HSCT-TMAs
Omeros Corporation · 2021–2025Contract
SRA 211471-01

Completed grants (7)

PI
Defibrotide in endothelial cell injury and platelet activation syndromes
Jazz Pharmaceuticals, Inc. · 2021–2023Contract
SRA 220298-01
PI
Decision tree analysis to determine optimal treatment duration in aHUS
Alexion Pharmaceuticals, Inc. · 2021–2023Contract
SRA 210243-01
PI
Role of defibrotide in modulating platelet reactivity and EC injury induced by TTP and aHUS-type TMA patient plasmas: correlation of in vitro assays with in vivo biomarkers.
Jazz Pharmaceuticals, Inc. · 2020–2021Contract
SRA 203093-01
PI
Role of defibrotide in modulating microvascular endothelial cell pathology induced by plasmas from patients with primary and secondary thrombotic microangiopathies
Jazz Pharmaceuticals · 2018–2019Contract
SRA 170407-01
PI
Mechanisms of HIV/ART Related Cardiac Fibrosis
National Heart, Lung, and Blood Institute · 2014–2017
R21HL125044-02 EW
PI
Molecular basis for HIV therapy-linked osteopenia
NIDDK · 2005–2011 · via NIH RePORTER
R01DK065511-04
PI
THE ENDOTHELIAL CELL IN PATHOGENESIS OF TTP
NHLBI · 1995–2007 · via NIH RePORTER
R01HL055646-09

1

1

Completed & closed trials (1)

PI
Decision Tree Analysis to Determine Optimal Treatment Duration in Atypical Hemolytic Uremic Syndrome (aHUS)
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)

COVID-19, Vaccines and Abnormal Blood Clotting
April 15, 2021
Hematology and oncology specialist Dr. Jeffrey Laurence answers questions about the connection between blood clotting, COVID-19 and vaccines.
What Is Known About COVID-19 and Abnormal Blood Clotting
July 2, 2020
Hematology and oncology specialist Dr. Jeffrey Laurence answers questions about the connection between blood clotting and other symptoms of severe COVID-19.

Novartis Pharmaceuticals Corporation

Alexion Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Foundation for AIDS Research (amfAR), The · Sanofi S.A.